Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Ann Rheum Dis. 2018 Apr 13;77(8):1187–1193. doi: 10.1136/annrheumdis-2017-212905

Table 2.

Risk of Hospitalized Allopurinol-Associated Severe Cutaneous Adverse Reactions (AASCARs) according to Combined Demographic Profiles

Variable High-Risk Race/Ethnicity Low-Risk Race/Ethnicity
Risk of Hospitalized AASCARs (/1000 persons) Multivariable-Adjusted Relative Risk* Risk of Hospitalized AASCARs (/1000 persons) Multivariable-Adjusted Relative Risk*
Female ≥60 years 1.50 (1.16 to 1.90) 12.25 (6.46 to 23.25) 0.53 (0.38 to 0.72) 3.99 (2.01 to 7.89)
<60 years 1.01 (0.70 to 1.41) 7.87 (3.95 to 15.66) 0.24 (0.13 to 0.42) 1.90 (0.82 to 4.38)
Male ≥60 years 0.83 (0.56 to 1.18) 6.59 (3.28 to 13.26) 0.10 (0.03 to 0.23) 0.82 (0.29 to 2.37)
<60 years 0.47 (0.21 to 0.57) 2.76 (1.28 to 5.95) 0.13 (0.07 to 0.23) 1.0 (reference)
*

Adjusted for chronic kidney disease and initial allopurinol dose.